Overactive Bladder Treatment Market is Expected to Reach $4,916.3 Million by 2026

ABOUT THIS REPORT

OVERVIEW

Overactive Bladder Treatment Market is expected to reach $4,916.3 million by 2026; growing at a CAGR of 3.0% till 2026.

Overactive bladder (OAB) is a condition that causes a sudden urge to urinate. The urge is difficult to stop, and it may lead to the involuntary loss of urine. The medication for overactive bladder relaxes the bladder, helpful for relieving symptoms of overactive bladder and reducing episodes of urge incontinence. The drug includes Tolterodine (Detrol, Detrol LA), Oxybutynin (Ditropan XL), Oxybutynin as a skin patch (Oxytrol), Trospium (Sanctura), Solifenacin (Vesicare), Oxybutynin gel (Gelnique, Gelnique 3%), Darifenacin (Enablex), Mirabegron (Myrbetriq), and Fesoterodine (Toviaz).

The rising prevalence of overactive bladder has increased the demand for overactive bladder treatment. For instance, globally, around 16% of adults have symptoms of overactive bladder, and the prevalence increases with age. Overactive bladder affected an estimated 33 million people in the USA in 2018. In the U.S.A, around 16% of men and 17% of women over 18 years old have overactive bladder (OAB). The prevalence of overactive bladder is 36.8% in women between the ages of 20 and 45 in 2018. 1 in 5 adults over 40 are affected by OAB or recurring symptoms of urgency and frequency. Overactive bladder (OAB) affects more than 22 million people in Europe. Around 21% of the overactive bladder population is suffering from incontinence, giving an overall prevalence of 11.4% for urge incontinence among Asian females.

Anticholinergics, Mirabegron, Botox, and Others in the type segment of the market scope, and the distribution channel segment is categorized into Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity. The report covers the value of the global market by type and distribution channel.

The market value of Anticholinergic was USD XX million in 2019, and it is expected to reach USD XX million by 2026, growing at a CAGR of XX during 2020-2026. Anticholinergic is the dominant segment and accounted for approximately 78.98% of the market in 2019, due to the increasing adoption of anticholinergic. Oxybutynin is the most efficient anticholinergic for overactive bladder. Oxybutynin reduces muscle spasms of the urinary tract and bladder. Oxybutynin is used to treat urgent urination, incontinence (urine leakage), and increased night-time urination.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global overactive bladder treatment Value figures. While North America is further categorized into enhancing the United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America overactive bladder treatment market was USD XX million in 2019, and it is predicted to reach USD XX million by 2026, growing at a CAGR of XX during the forecast period. The regulatory approvals for overactive bladder drug would improve the growth of the market.

Major players operating in the overactive bladder treatment industry include Astellas Pharma Inc., Pfizer, Inc., Teva Pharmaceutical Industries Limited, Allergan, PLC, Mylan N.V, Endo International PLC, Hisamitsu Pharmaceutical Co., Inc., Sanofi, Aurobindo Pharma Limited, Johnson & Johnson.

Formation of strategic partnership and commercialization of regulatory approved treatment for overactive bladder are the few business strategies adopted by the key companies, with a focus on maintaining a competitive advantage over others. The companies are focused on the expansion of business activities on a global scale by signing the agreement with suppliers of raw materials for overactive bladder drugs. For instance, Codexis, Inc., has signed a supply agreement with KYORIN Pharmaceutical Co., Ltd. to supply the proprietary enzyme used in the manufacturing of vibegron, an active ingredient in Beova Tablets, for the treatment of overactive bladder.